Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Anabolic Therapy Study (CAT)
NCT06558188Phase 4Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2025
- Primary completion
- Nov 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in postmenopausal osteoporosis comparing Romosozumab with Romosozumab and Teriparatide (2 arms). Primary endpoint: Lumbar spine areal bone mineral density at 12 months. Started Feb 2025; status: recruiting.
02
Drugs
romosozumabteriparatide
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT06558188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06558188.